1. Home
  2. MLSS vs NEUP Comparison

MLSS vs NEUP Comparison

Compare MLSS & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Milestone Scientific Inc.

MLSS

Milestone Scientific Inc.

HOLD

Current Price

$0.28

Market Cap

22.1M

Sector

Health Care

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.72

Market Cap

23.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLSS
NEUP
Founded
1989
1996
Country
United States
United States
Employees
N/A
8
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.1M
23.8M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
MLSS
NEUP
Price
$0.28
$4.72
Analyst Decision
Buy
Strong Buy
Analyst Count
1
2
Target Price
$1.00
$21.00
AVG Volume (30 Days)
996.3K
47.8K
Earning Date
05-14-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,973,982.00
N/A
Revenue This Year
$12.64
N/A
Revenue Next Year
$8.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.99
N/A
52 Week Low
$0.22
$3.65
52 Week High
$1.11
$21.31

Technical Indicators

Market Signals
Indicator
MLSS
NEUP
Relative Strength Index (RSI) 47.90 59.82
Support Level $0.27 $3.91
Resistance Level $0.30 $5.06
Average True Range (ATR) 0.02 0.26
MACD -0.00 0.04
Stochastic Oscillator 38.04 100.00

Price Performance

Historical Comparison
MLSS
NEUP

About MLSS Milestone Scientific Inc.

Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: